This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International US West
Mark Your Calendar for BPI US West 2024!
March 11-14, 2024Town and Country Resort, San Diego

John Li
Director - RNA Drug Substance at Capstan Therapeutics


John J. Li is the Director of RNA Drug Substance at Capstan Therapeutics where he focuses on process development, technology innovation and CMC for RNA therapeutics. John has broad technical experience in platform process design with respect to various drug modalities such as Monoclonal antibody, Antibody variants, ADC, AAV/Lentivirus, Plasmid DNA, and recombinant proteins. He holds a PhD in Structural Biology from the University of Toronto, Canada where he studied protein kinase catalytic mechanisms and inhibition by x-ray crystallography.

Agenda Sessions

  • Towards Developing mRNA Platform Process: Lessons from Other Modalities

  • The Future for RNA-based Therapeutics